

Tuesday, 12 September 2023

**Mr Michael Alscher resumes role of Chair**

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) wishes to advise the market that Mr Michael Alscher will return to his role as Chair of the Company with effect from today. Accordingly, Mr Daren McKennay will cease to act as Michael's alternate director and cease to be Acting Chair from the same date.

ACL would like to thank Daren for providing the Company with his expertise and guidance during the last few months.

**– ENDS –**

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

**Investors**

Eleanor Padman

Company Secretary

Email: [investors@clinicallabs.com.au](mailto:investors@clinicallabs.com.au)

Phone: +61 (0) 422 002 918

**About Australian Clinical Labs**

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.